H ave you ever been asked by a patient or another health care professional about a major change in drug labeling that they learned about while watching the news, reading the newspaper, or listening to the radio and you found that you knew nothing about it? Recent situations in which this may have happened may be a result of announcements made by the Food and Drug Administration that they would be requiring manufacturers to make the following changes in product labeling: • All labeling for sedative-hypnotic drug products must change to reflect the risk of severe allergic reactions and complex sleeprelated behavior, including driving, making phone calls, and preparing and eating food (while asleep). • Increased risk of fractures in female patients treated with pioglitazone and rosiglitazone therapy must be stated on the label. • Increased chance of cardiovascular risk and adverse psychiatric symptoms in patients using central nervous system stimulants for the treatment of attention deficit hyperactivity disorder must be stated on the label. • Increased chance of serious and life-threatening side effects or death with the use of erythropoiesis-stimulating agents in patients with cancer must be stated on the label.
• The risk of serious and lifethreatening allergic reactions in patients treated with omalizumab must be stated on the label. • Labeling changes to telithromycin must be made to reflect the removal of two indications (acute bacterial sinusitis and exacerbations of chronic bronchitis) and strengthening of the warnings related to the risk of hepatotoxicity, loss of consciousness, visual disturbances, and use of the drug in patients with myasthenia gravis. It is possible to rapidly fall behind on late-breaking news with our busy schedules, but that does not mean that we have to be out of touch with this type of important information. The easiest way to keep up with these press releases is to have the announcements emailed to you. This will allow you to learn about these changes at the same time as the media, instead of learning about the changes from the media, your patients, or other health care professionals.
The announcements sent out through this system focus on clinically important medical-product safety issues. The e-mails contain a concise summary of the safety alert and a hyperlink that can direct you to the MedWatch Web site where you can get more detailed information (see Figure 1 ). 
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Subscribing to this free service is easy and only takes a few moments to complete. The subscription's Web address is: https:// list.nih.gov/cgi-bin/wa?SUBED= medwatch&A=1. Once the form is completed and submitted, you will begin to receive these valuable announcements. This will allow you to no longer be dependent on the media to keep you up-to-date with drug safety issues. Furthermore, you will not miss any important announcements during your absence if you go on vacation.
I encourage all health care professionals to subscribe to this valuable and free service provided by the Food and Drug Administration and their MedWatch program. ■
